On Tuesday, LG Display Co Ltd. (ADR) (NYSE:LPL)’s shares inclined 0.20% to $11.59.
Independa, partnership with LG Electronics, declared the launch of its ecommerce website. The new site provides a portal by which consumers can purchase an IndependaTV, the quintessential platform for providing advanced remote engagement and care for the Greatest Generation.
Up to this point, Independa was only accessible through enterprise outlets like care facilities and retirement communities. Independa’s television platform provides a broad range of services counting photo sharing, video chats, message sharing, a call button, and appointment and medication reminders. These features are built directly into an LG constructed television monitor, allowing for plug and play capabilities by the end user. LG is a planned partner and Independa investor.
Independa has been blazing the trail in the new age of elder care, guiding the industry into the 21st century. Independa has software inside LG commercial TVs, creating the world’s first and only TV with embedded remote engagement and care services. This has garnered Independa a 2015 CES Innovation Award and recognition from Entrepreneur Magazine as a Brilliant 100 Company.
LG Display Co., Ltd. manufactures and sells thin film transistor liquid crystal display (TFT-LCD) panels in the Republic of Korea, the United States, Europe, and Asia. It offers various display panels comprising large-sized panels for use in televisions, notebook computers, and desktop monitors; and small-sized panels for other application products, such as mobile phones and tablet computers.
Prudential Financial Inc (NYSE:PRU)’s shares gained 0.26% to $87.52.
Prudential Mortgage Capital Company recently declared organizational changes to strengthen its operational infrastructure as the company seeks to expand within an increasingly competitive market. Prudential Mortgage Capital Company is the commercial mortgage lending business of Prudential Financial, Inc. (PRU).
Paige Warren has stepped into the newly created role of chief operating officer from her current position as head of affordable housing finance in addition to Prudential Huntoon Paige, the firm’s FHA lending business. Hal Collett, president of the company’s servicing business, Prudential Asset Resources, has been named president of Huntoon Paige; and Wells Fargo veteran Tim Seward joins the company as President of Prudential Asset Resources, PMCC’s asset administration and servicing group. The appointments were made effective June 25, 2015.
Prudential Financial, Inc. provides insurance, investment administration, and other financial products and services to individual and institutional customers in the United States and internationally. The company principally offers life insurance, annuities, retirement-related services, mutual funds, and investment administration products. Its U.S. Retirement Solutions and Investment Administration division offers individual variable and fixed annuity products; recordkeeping, plan administration, actuarial advisory, tailored participant education and communication, trustee, and institutional and retail investments services; and guaranteed investment contracts, funding agreements, institutional and retail notes, structured settlement annuities, and other group annuities. This division also provides investment administration and advisory services to the public and private marketplace.
At the end of Tuesday’s trade, Dresser-Rand Group Inc. (NYSE:DRC)‘s shares surged 0.01% to $85.18.
Skyworks Solutions Inc (SWKS) declared that its Board of Directors has declared a cash dividend of $0.26 per share of the Company’s common stock, representing a 100 percent enhance from the prior quarterly dividend of $0.13 per share. Based on the closing price of Skyworks’ stock on June 17, 2015, the raised dividend represents roughly a one percent yield, or $1.04 per share on an annualized basis. The dividend is payable on August 27, 2015, to stockholders of record as of the close of business on August 6, 2015.
Skyworks Solutions, Inc., together with its auxiliaries, designs, develops, manufactures, and markets analog and mixed signal semiconductors worldwide. Its product portfolio comprises amplifiers, attenuators, battery chargers, circulators, DC/DC converters, demodulators, detectors, diodes, directional couplers, filters, front-end modules, hybrids, infrastructure radio frequency subsystems, isolators, LED drivers, mixers, modulators, optocouplers, optoisolators, phase shifters, phase locked loops/synthesizers/VCOs, power dividers/combiners, power administration devices, receivers, switches, technical ceramics, and voltage regulators.
XOMA Corp(NASDAQ:XOMA), ended its Tuesday’s trading session with 6.01% gain, and closed at $3.88.
XOMA Corp (XOMA) declared XOMA 358, a fully human allosteric monoclonal antibody that reduces both the binding of insulin to its receptor and downstream insulin signaling, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of congenital hyperinsulinism (HI).
Orphan drug designation is granted by the FDA Office of Orphan Products Development (OOPD) to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the United States. The designation provides the drug developer with a seven-year period of U.S. marketing exclusivity, in addition to tax credits for clinical research costs, the ability to apply for annual grant funding, clinical research trial design assistance, and waiver of Prescription Drug User Fee Act (PDUFA) filing fees. The OOPD also works on rare disease issues with the medical and research communities, professional organizations, academia, governmental agencies, industry, and rare disease patient groups.
XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company’s lead product candidate comprises gevokizumab, a proprietary humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III clinical trial for NIU and Behçet’s disease uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, autoimmune inner ear disease, and cardiovascular diseases, in addition to diseases under the neutrophilic dermatoses designation, Schnitzler syndrome, and other diseases; and various proof-of-concept studies comprising polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
